2011 E-Update Number 5


Donate
In this Issue
Dr. Futreal Joins CFCF BOSA
Two New Grants Awarded
Lauren Blogs About Research Progress
Country Music Marathon
Advertisement from our Sponsor
NVS logo
CFCF is pleased to announce that this E-Update is supported by Novartis Pharmaceuticals Corporation
Follow us on Twitter!
 
Join us on Facebook!
 
Visit us on Navigating Cancer! 
Survivor Stories
Daniel Birns 
(submitted 3/22/11)
  
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients.

Read our newest survivor stories:
Join Us for a Cure
seatle to portland 08

Make a difference and get involved with CFCF!  Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events!
Quick Links...
Give hope and a future to  neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible.  We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible. 

Donate

To learn more, view CFCF's:
Audited Financial Statements
IRS Form 990

Caring for Carcinoid Foundation
198 Tremont Street, Box 456
Boston, MA 02116
617.948.2514
www.caringforcarcinoid.org
CFCF meets all 20 Wise Giving Alliance standards for charity accountability established by the Better Business Bureau. Click here to check out the CFCF Wise Giving Report.
Dr. Futreal Joins Board of Scientific Advisors

Dr. Andy FutrealCFCF is honored to announce that Dr. Andy Futreal has joined our esteemed Board of Scientific Advisors.


"I am delighted to be joining the Board of Scientific Advisors for the Caring for Carcinoid Foundation. The work they are doing in focusing attention on this cancer type and funding cutting edge research into the causes and potential avenues for treatment are both exciting and exemplary. I look forward to working with the other members of the Board and the Foundation in this important effort." - Dr. Futreal

Dr. Futreal is co-founder and director of the Cancer Genome Project and a senior investigator at the Wellcome Trust Sanger Institute. Currently, Dr. Futreal is focused on expanding characterization of cancer to whole genome sequencing and applying this knowledge to impact cancer treatments.

Click here for Dr. Futreal's Bio and here to learn more about CFCF's highly regarded Board of Scientific Advisors.
Two New Grants Awarded to NET Researchers
AACR

The Caring for Carcinoid Foundation is pleased to announce two research grants awarded through a partnership with the American Association for Cancer Research (AACR). Both of these grants, each awarding of $250,000 over two years, will allow investigators to explore new, targeted strategies for treating neuroendocrine cancer patients.

 

"CFCF's partnership with AACR is a critical component of our strategy to achieve a cure. To succeed, we believe it will take top scientists to achieve an understanding of neuroendocrine tumors at their basic scientific level. Partnering with AACR, one of the premier research associations in the country, will enable CFCF to attract some of the nation's most talented scientists to carcinoid and neuroendocrine cancer research. I am also grateful to our research partners, the Raymond and Beverly Sackler Fund for the Arts and Sciences, for their generous funding of two additional fellowships to attract young investigators to the field. The future is exciting for carcinoid and related neuroendocrine cancer research." - CFCF Founder Nancy Lindholm 

 

The 2011 recipients are:  

Oncolytic Viral Therapy for Neuroendocrine Cancers

Charles Rudin, M.D., Ph.D., Johns Hopkins University

 

This innovative project will study the only anti-cancer virus with selective affinity for neuroendocrine tumor cells and define the population of neuroendocrine patients most likely to respond to the Seneca Valley Virus.

 

Suppression of Neuroendocrine Tumors Via Epigenetic Regulation

Xianxin Hua, M.D., Ph.D., the University of Pennsylvania  

 

By targeting the pathway regulated by menin, a tumor suppressor that is mutated in patients with inherited Multiple Endocrine Neoplasia Type I (MEN1) syndrome, Dr. Hua's study seeks to uncover a novel treatment strategy for patients with neuroendocrine tumors.

 

Please click here for the press release issued by the AACR.

Lauren Blogs About Research Progress at CFCF

Lauren Erb

In her latest blog posting, CFCF Executive Director Lauren Erb writes about the exciting research developments here at the Caring for Carcinoid Foundation. She welcomes Dr. Futreal to the Board of Scientific Advisors, discusses CFCF's collaboration with AACR on two new projects, and remarks on the expanding field of researchers pursuing cures for patients with neuroendocrine cancers.

Jacob and Payton Inspire the Country Music Marathoners

On April 30,  the family and friends of Jacob Carwile and Payton Farnell Graeber will honor the memories of

Payton

their loved ones by running the Country

Music Marathon and Half-Marathon.

 

Please consider supporting Team Jacob (Jacob) and The Little Team That Could (Payton) in their race against carcinoid and related neuroendocrine cancers.

Advertisement from our Sponsor

 iWalk for Carcinoid  FDA MedWatch Full Prescribing Information